Source comparison
Thymosin Alpha-1 SubQ vs IM: Administration Comparison
Time to Peak Plasma Concentration 2–3 hours 60–90 minutes SubQ delivers sustained elevation; IM creates sharper peak Bioavailability (AUC) 15–20% higher systemic exposure Standard baseline SubQ produces more peptide availability per mg administered Absorption
This comparison does not assign a generated winner or score.
- Time to Peak Plasma Concentration
- 2–3 hours
- 60–90 minutes
- SubQ delivers sustained elevation; IM creates sharper peak
- Bioavailability (AUC)
- 15–20% higher systemic exposure
- Standard baseline
- SubQ produces more peptide availability per mg administered
- Absorption Variability (CV%)
- 14%
- 28%
- SubQ offers better reproducibility across subjects
- Injection-Site Pain (VAS 0–10)
- 1.2 immediately, 0.3 at 24h
- 3.8 immediately, 2.1 at 24h
- SubQ causes significantly less discomfort
- Lymphatic Exposure
- High. Peptide drains through regional nodes
- Low. Bypasses lymphatic staging
- SubQ aligns with immune-modulation mechanism
- Needle Length Required
- 5/16" to 1/2"
- 1" to 1.5"
- SubQ requires less precision in technique